NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Autor: Vilde Drageset Haakensen, Anna K. Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M. Cedres, Åslaug Helland

Publikováno v: Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-9 (2021)

Abstract Background Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and nivolumab has recentl

Externí odkaz: https://doaj.org/article/64fe1d0ba38a4b3f9fc9f05cfd5c3739

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

Autor: Espen Basmo Ellingsen, Sara M. Mangsbo, Eivind Hovig, Gustav Gaudernack

Publikováno v: Frontiers in Immunology, Vol 12 (2021)

Telomerase-based therapeutic cancer vaccines (TCVs) have been under clinical investigation for the past two decades. Despite past failures, TCVs have gained renewed enthusiasm for their potential to improve the efficacy of checkpoint inhibition. Telo

Externí odkaz: https://doaj.org/article/30234e96de2c4b39a94c643d1ef45637

Therapeutic cancer vaccination against telomerase: clinical developments in melanoma

Autor: Espen Basmo Ellingsen, Jens Bjørheim, Gustav Gaudernack

Publikováno v: Current Opinion in Oncology. 35:100-106

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56cac7f6a3af091c975a87e7e9605cca
https://doi.org/10.1097/cco.0000000000000922

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Autor: Åslaug Helland, Vilde Drageset Haakensen, Maria Moksnes Bjaanæs, Saima Jamil Farooqi, Espen Basmo Ellingsen, Anna K. Nowak, Oscar Grundberg, Henrik Horndalsveen, Tine McCulloch, Susana Cedres

Publikováno v: Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-9 (2021)
Haakensen, V D, Nowak, A K, Ellingsen, E B, Farooqi, S J, Bjaanæs, M M, Horndalsveen, H, Mcculloch, T, Grundberg, O, Cedres, S M & Helland, Å 2021, ' NIPU : a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma ', Journal of Translational Medicine, vol. 19, no. 1, 232 . https://doi.org/10.1186/s12967-021-02905-3
Journal of Translational Medicine
Scientia

Background Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and nivolumab has recently shown i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1414c05d37719c0f46f3778385b64a97
http://hdl.handle.net/10852/86272

A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update

Autor: Wenche Rasch, Espen Basmo Ellingsen, Elin Aamdal, Else Marit Inderberg, Tormod Kyrre Guren, Eivind Hovig, Gustav Gaudernack, Marta Nyakas, Steinar Aamdal, Paal Brunsvig

Publikováno v: Journal of Clinical Oncology. 38:62-62

62 Background: Combining checkpoint blockade with a cancer vaccine may induce broader immune responses, leading to better clinical outcomes. UV1 targets the enzyme telomerase (hTERT) which is expressed in almost all cancer types and is essential for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::165c7b7f88fe8416a1db4ad2ffaa8a1e
https://doi.org/10.1200/jco.2020.38.5_suppl.62